Advertisement
Advertisement

LEXX

LEXX logo

Lexaria Bioscience Corp. Common Stock

0.75
USD
Sponsored
-0.01
-1.83%
Jan 29, 15:54 UTC -5
Closed
exchange

After-Market

0.76

+0.01
+1.20%

LEXX Earnings Reports

Positive Surprise Ratio

LEXX beat 6 of 15 last estimates.

40%

Next Report

Date of Next Report
Apr 13, 2026
Estimate for Q2 26 (Revenue/ EPS)
$102.00K
/
-$0.12
Implied change from Q1 26 (Revenue/ EPS)
--
/
+71.43%
Implied change from Q2 25 (Revenue/ EPS)
-41.38%
/
-20.00%

Lexaria Bioscience Corp. Common Stock earnings per share and revenue

On Jan 13, 2026, LEXX reported earnings of -0.07 USD per share (EPS) for Q1 26, beating the estimate of -0.13 USD, resulting in a 47.21% surprise. Revenue reached --, compared to an expected 102.00 thousand, with a -100.00% difference. The market reacted with a +5.08% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 102.00 thousand USD, implying an increase of 71.43% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q1 2026, Lexaria Bioscience Corp. Common Stock reported EPS of -$0.07, beating estimates by 47.21%, and revenue of $0.00, -100% below expectations.
The stock price moved up 5.08%, changed from $0.77 before the earnings release to $0.81 the day after.
The next earning report is scheduled for Apr 13, 2026.
Based on 3 analysts, Lexaria Bioscience Corp. Common Stock is expected to report EPS of -$0.12 and revenue of $102.00K for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement